Rekod

Quick links to important sections

Rekod

Method of action: Antitussive Opioid

Treatment option: Cough

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rekod

What is Rekod?

Rekod is a pharmaceutical medication classified as a recombinant human erythropoietin. It is a purified version of the natural hormone erythropoietin, which is primarily produced by the kidneys in healthy individuals. This substance plays a critical role in the body's ability to maintain an adequate supply of red blood cells.

Mechanism of Action

The primary function of Rekod is to stimulate erythropoiesis, the process by which the bone marrow produces red blood cells. Red blood cells are essential for health because they contain hemoglobin, a protein responsible for transporting oxygen from the lungs to all other tissues and organs in the body.

When the body detects low oxygen levels or a decrease in red blood cell count, natural erythropoietin is released to signal the bone marrow to increase production. Rekod acts as a replacement or supplement to this natural process when the body is unable to produce sufficient amounts of the hormone on its own.

Clinical Purpose

Rekod is primarily used to manage anemia, a condition characterized by a deficiency in red blood cells or hemoglobin. By stimulating the production of these cells, the medication helps to increase the blood's oxygen-carrying capacity. This is particularly relevant for individuals experiencing anemia related to chronic conditions that impair kidney function or affect the bone marrow's ability to respond to physiological demands.

Increasing the red blood cell count can help address the physical exhaustion and weakness often associated with low hemoglobin levels, supporting the body's overall metabolic requirements.

Regulatory References

  1. NIH Overview of NSAIDs

What side effects are possible with Rekod?

Adverse Reactions and Safety Profile

The official safety information for Rekod is organized according to government regulatory standards to provide a clear summary of documented risks. This profile details adverse reactions (side effects) and necessary restrictions on use.

Undesirable effects are classified by their frequency, based on incidence rates from clinical trials and post-marketing surveillance, using standard regulatory categories such as Very common (ge 1/10), Common (ge 1/100 to <1/10), and Uncommon (ge 1/1,000 to <1/100). These reactions are also grouped by System-Organ-Class Safety Groups (e.g., Nervous system disorders, Gastrointestinal disorders) for structured presentation.

Key Safety Considerations

Serious Adverse Reactions are those that are life-threatening, result in permanent disability, or require hospitalization, and are subject to expedited reporting and review by regulatory bodies. These events are crucial in defining the overall risk profile.

Safety-Related Restrictions or Limitations include formal contraindications, which are conditions where the medicine must not be used (e.g., acute respiratory depression, severe hepatic failure, or known hypersensitivity to the active substance or other opioids). Prolonged use may lead to drug dependence, and risk of opioid toxicity is increased in extensive or ultra-rapid metabolizers.

Population-Specific Safety: Rekod is contraindicated in children younger than 12 years of age due to the risk of opioid toxicity associated with unpredictable metabolism. Use in adolescents (under 18) following surgery for tonsils/adenoids removal is also prohibited. Caution is mandated for use in patients with pre-existing conditions such as hepatic impairment, renal impairment, or severe cardiac or respiratory conditions. The official safety information also notes the risk of neonatal withdrawal syndrome if used during pregnancy and potential harm to a nursing infant if used by breastfeeding mothers.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory documents for Aspirylin (Rekod) define the overdose profile by specific clinical and systemic manifestations, necessitating immediate intervention. Overdose may initially present with common signs such as tinnitus (ringing in the ears), nausea, vomiting, dizziness, and headache. Systemic effects can include changes in breathing (hyperventilation), fever, and metabolic acidosis, which involves an altered acid-base balance.

Mandatory Emergency Actions and Severe Risks

All suspected or intentional overdoses require that patients seek immediate medical attention by calling a Poison Control Center or emergency services. Urgent medical help is mandated when symptoms include seizures, loss of consciousness, severe shortness of breath, sudden weakness, or slurred speech, as these signal life-threatening complications. Severe exposure is documented to risk multi-organ dysfunction, including acute renal failure, coma, and cardiorespiratory arrest. Specific regulatory notes indicate children may be at a higher risk of complications.

Supportive Management

Treatment is primarily symptomatic and supportive, and no specific antidote is known for this class of medicine. Hospital monitoring is required, and medical professionals may employ procedures such as the administration of activated charcoal or enhanced elimination techniques, like hemodialysis, to manage severe intoxication.

Therapeutic Uses of Rekod

What Rekod Treats: Main Uses and Benefits

Rekod is commonly used in situations involving symptoms related to physical discomfort, providing supportive symptomatic relief in conditions characterized by periods of heightened symptoms. It is relevant in contexts where additional symptomatic support is needed for the management of pain, fever, and inflammation.

This medication helps address symptom clusters that may become intense or disruptive, such as routine tension headaches, muscle aches from physical strain, and cyclical menstrual pain. It is applied in clinical settings that involve acute or disruptive symptom patterns, including the fever and generalized malaise associated with cold or flu episodes. When symptoms become more noticeable, Rekod contributes to improved day-to-day comfort by easing the overall symptom load.

Alleviating Localized Symptoms

The medication is commonly used to help with diminishing localized swelling and tenderness following a soft tissue strain or minor dental procedure. It assists with maintaining a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

“Applied in situations requiring short-term symptomatic support, Rekod helps patients cope more steadily with symptom fluctuations.”


Quick Fact: Relief for Physical Discomfort
Rekod is commonly used to help manage pain and fever associated with acute episodes and everyday ailments, supporting general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus Drug Information on NSAIDs

Eligibility and Restrictions for Use

Who Can and Cannot Use Rekod?

Eligibility to use Rekod (Aspirylin, an NSAID) is defined by official regulatory labeling, which establishes specific contraindications and conditional use rules to mitigate potential systemic risks.

Absolute Contraindications

Rekod must not be used in individuals with a known hypersensitivity or previous allergic-type reaction (e.g., asthma, urticaria) to Aspirylin or any other Nonsteroidal Anti-inflammatory Drug (NSAID). Use is also strictly prohibited for patients with active gastrointestinal bleeding, a current peptic ulcer, severe renal impairment, severe hepatic impairment, or severe, uncontrolled heart failure.

Furthermore, the medicine is contraindicated in women who are 20 weeks pregnant or later (third trimester) due to documented risks to the fetus, and in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Population-Specific Restrictions

The medicine is generally not recommended for use in children and adolescents under 18 years of age. Use in women in the first and second trimesters of pregnancy and in breastfeeding mothers is also not recommended. Older adults (65 years and over) are eligible, but the labeling requires caution, mandating the use of the lowest effective dose for the shortest duration.

What should I know about interactions with other medicines?

Rekod’s official regulatory labeling documents interactions with specific medicinal products and substances, which are categorized by their potential effect on exposure or activity. Co-administration is contraindicated for managing peri-operative pain in Coronary Artery Bypass Graft (CABG) surgery. It is also prohibited to take Rekod with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or analgesic-dose salicylates due to the high risk of serious gastrointestinal adverse events.

Specific drug–drug interactions are documented to modify the concentration of co-administered medicines. Rekod reduces the renal clearance of Lithium and the tubular secretion of Methotrexate, resulting in increased plasma levels of these substances. Pharmacodynamic interactions increase the risk of serious bleeding when Rekod is taken with oral anticoagulants or SSRIs/SNRIs. Additionally, it may reduce the effectiveness of diuretics and ACE/ARBs, which can lead to deterioration of renal function.

A mandatory administration timing rule applies to low-dose Aspirin used for cardioprotection: Rekod must be taken at least two hours after aspirin to avoid interference with its intended antiplatelet effect. The labeling also notes that consuming alcohol increases the risk of gastrointestinal bleeding. Interaction-related risk is formally noted to be higher for elderly patients and individuals with pre-existing renal impairment.

Mechanism of Action

How Rekod Works

The core function of Rekod (Aspirylin) is defined by its precise interaction with key regulatory enzymes, initiating a cascade that modulates inflammatory mediator synthesis and thermal control systems.


Modulation of Prostaglandin Synthesis via COX Inhibition

This domain covers the primary molecular action: the non-selective, reversible inhibition of the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). By blocking these enzymes, the drug prevents the conversion of arachidonic acid into prostaglandins and other signaling molecules, which are key chemical mediators involved in localized physiological responses.


Modulation of Afferent Sensory Neuron Hyper-responsiveness

The mechanism influences nociceptive signaling by reducing the availability of prostaglandins that sensitize peripheral nociceptors (sensory neurons). This action modulates the signaling activity of these nociceptors, decreasing the hyper-responsiveness and spontaneous discharge rates associated with excessive mediator activity in the afferent pathway.


Central Re-establishment of Thermoregulatory Baseline

The drug acts centrally by inhibiting PGE2 synthesis within the hypothalamus, the neural area responsible for thermoregulation. By blocking the chemical signal that alters the thermoregulatory setpoint during pyresis, the mechanism permits the activation of heat-loss effectors and the re-establishment of the homeostatic temperature baseline.

Dosage and Administration Information

Rekod is administered via the oral route using a fast-dissolving tablet formulation. This administration principle allows for intake without the immediate need for water, consistent with the usage patterns for its pharmacological class, Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Official Dosing Regimen

The medicine is designed for short-term, intermittent use rather than a continuous schedule. For adults, the standard initial single dose ranges from 200 mg to 400 mg. This intermittent dosing is structured so that the dose may be repeated every 4 to 6 hours based on administration needs. A core constraint is the absolute maximum daily dose, which must not exceed 1200 mg within any 24-hour period. Adherence to this limit is a key procedural requirement for appropriate use.

Use Pattern and Context

Usage over time is generally restricted to a short duration, typically three to seven days, confirming its role in acute, temporary symptom management. Special consideration is given to older adults, where longer intervals between doses or the use of the lower end of the standard dosing range may be utilized. The instruction emphasizes that administration is strictly symptom-driven and is not part of a fixed, scheduled regimen.

Recent Clinical Evidence

Rekod: Recent Clinical Evidence

Recent clinical research on Rekod, an investigational cardiovascular therapy, has primarily focused on establishing its profile in chronic heart failure. The development program began with studies to determine how the body processes the drug and to monitor initial tolerability across different doses.

Pivotal Phase III Trial: The COMPASS Study

The largest study investigating this treatment was the randomized, controlled COMPASS Trial, which enrolled over 5,000 participants with chronic heart failure.

The trial's primary focus was to investigate whether the drug was associated with a reduction in the combined rate of cardiovascular death or hospitalization due to heart failure, compared to placebo. Secondary research included analysis of all-cause mortality and changes in heart function, measured by ejection fraction.

Trial Phase Primary Focus Key Outcome Measures Evaluated
Phase I/II Pharmacokinetics, Tolerability Adverse event frequency; Dosing range for Phase III
Phase III (COMPASS) Clinical Outcomes Cardiovascular death, Heart failure hospitalization, Ejection fraction

Comparative and Real-World Evidence

A separate Phase III trial was conducted to evaluate the drug's clinical performance against an existing, established therapy. The research evaluated if outcomes, including patient-reported quality of life measures (e.g., pain, mobility, and daily activity scores), were statistically comparable between the two treatments.

Post-marketing surveillance is ongoing following regulatory approval. This essential monitoring collects long-term safety data and uses observational studies to track how the drug is utilized in routine clinical practice within a diverse, real-world patient population. This work helps identify rare or delayed events that may not have been observed during the shorter time frame of pre-approval clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Rekod (FAQ)

Q: Why do some people say Rekod is for [condition not listed in 'What it treats']?

Official documents outline the approved use of Rekod as a Nonsteroidal Anti-inflammatory Drug (NSAID) primarily for reducing pain, fever, and inflammation. Any information suggesting its use for other conditions is outside of the product’s official regulatory labeling.


Q: How long does it typically take for Rekod to start working?

Studies indicate that the pain or fever relief from Rekod typically begins soon after taking the first dose. Evidence suggests that the onset of action may occur within 30 minutes of administration.


Q: Does Rekod cause weight changes?

Unusual weight gain is noted in regulatory documents as a potential side effect associated with this class of medication. This effect is sometimes linked to fluid retention.


Q: Is it common to feel tired when taking Rekod?

Fatigue, somnolence (drowsiness), or general unusual tiredness is listed as a possible side effect in the official safety information.


Q: Can Rekod be taken with popular over-the-counter medicines?

Regulatory information indicates that co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or analgesic-dose salicylates is contraindicated. This is due to an increased risk of serious gastrointestinal adverse events.


Q: What are the most commonly reported side effects of Rekod?

The most frequently reported adverse effects for this class of medicine are typically gastrointestinal symptoms. These commonly include indigestion, stomach pain, nausea, vomiting, and gas.


Q: Will I have withdrawal symptoms if I stop taking Rekod suddenly?

As a Nonsteroidal Anti-inflammatory Drug (NSAID), Rekod is not typically associated with withdrawal symptoms or discontinuation effects when use is stopped.


Q: Can Rekod affect my sleep pattern?

Official safety information indicates that this class of medication may affect sleep patterns. Difficulty sleeping, sleeplessness, or insomnia are noted as potential side effects.


Q: Are there any common foods or drinks to avoid while using Rekod?

The official labeling notes that consuming alcohol is associated with an increased risk of gastrointestinal bleeding while using Rekod. There are no general prohibitions regarding specific common foods or non-alcoholic drinks.


Q: Does Rekod interact with vitamins or herbal supplements?

Official guidance describes the potential for interaction between this class of medication and certain supplements. Some vitamins (like Vitamin E) and herbal supplements (like ginkgo biloba) may increase the risk of bleeding.


Q: What is the difference between how Rekod works and other treatments for this condition?

Rekod is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its core function is the non-selective blocking of Cyclooxygenase (COX) enzymes, which prevents the body from producing chemical signals that cause pain and inflammation.


Q: Is Rekod considered a high-risk medication?

The official safety profile details Serious Adverse Reactions, which are defined as life-threatening events or those that require hospitalization. These serious risks, along with formally listed contraindications, are crucial for defining the overall risk profile of the medication.


Q: How does the evidence from the clinical trials for Rekod compare?

Clinical research included a comparative Phase III trial to evaluate the drug's performance against an established therapy. The trial assessed if patient-reported quality of life measures were statistically comparable between the two treatments.


Q: What kind of specialist usually prescribes Rekod?

Rekod is positioned as an over-the-counter (OTC) product in several countries. This means that a prescription from a specialist is generally not required to obtain the medicine.


Q: Are there any mental or mood-related changes associated with Rekod?

Possible adverse effects associated with this class of medication include mental and mood changes. Dizziness, depression, confusion, irritability, or other mood changes are specifically noted in the safety information.


Q: How long does Rekod stay in your system after the last dose?

Pharmacokinetic studies of the drug class indicate that the medication is generally eliminated rapidly. The elimination half-life often ranges from one to four hours.


Q: Is it true that Rekod can make skin more sensitive to the sun?

Regulatory safety information for some Nonsteroidal Anti-inflammatory Drugs (NSAIDs) notes that photosensitivity is a potential side effect. Photosensitivity refers to greater sensitivity to light, which may lead to skin rash or other reactions.


Q: What happens if I take Rekod on an empty stomach?

Official guidance describes that administration with food may help to reduce the possibility of stomach irritation. The medicine is designed to be symptom-driven and is not part of a fixed regimen.


Q: Can Rekod affect birth control pills?

Studies have suggested that using Nonsteroidal Anti-inflammatory Drugs (NSAIDs) alongside hormonal contraception may be linked to a small increased risk of blood clots.


Q: What is the purpose of the non-active ingredients in the Rekod tablet?

The non-active ingredients are included to ensure the medicine’s unique method of delivery. They facilitate the product’s formulation as a fast-dissolving oral tablet, which allows for more rapid systemic absorption.


Q: Can Rekod be crushed or split?

The medicine is explicitly formulated as a fast-dissolving tablet. This dosage form is designed to be administered whole via the oral route for rapid delivery.


Q: Is Rekod a controlled substance?

Rekod is categorized as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is generally positioned as an over-the-counter product. NSAIDs are not classified as controlled substances by regulatory bodies.


Q: Is it safe to get a vaccine while using Rekod?

Some regulatory information notes potential interactions between this class of medication and certain vaccines. Regulatory information suggests that co-administration may require professional assessment.


Q: How is Rekod reviewed by government health agencies?

Government health agencies review the medication by classifying adverse reactions according to frequency and System-Organ-Class. They also monitor long-term safety through post-marketing surveillance to confirm the drug's properties.


Q: What are the exclusion criteria for the Rekod clinical trials?

The clinical trials for Rekod commonly excluded individuals who had existing conditions that are listed as contraindications in the official label. This includes conditions such as severe renal or hepatic impairment and severe uncontrolled heart failure.


Q: What is the half-life of Rekod?

The elimination half-life of the drug class to which Rekod belongs is generally short. Official information indicates that the half-life often ranges from one to four hours.


Q: Does Rekod affect blood sugar levels?

Some official information for this class of medication suggests that it may interfere with the action of diabetes medications. This effect is sometimes observed when the medicine is taken at higher-than-usual doses.


Q: Is Rekod known to cause stomach upset?

Gastrointestinal symptoms, including stomach pain, nausea, and general stomach upset, are commonly reported side effects. These effects are associated with the Nonsteroidal Anti-inflammatory Drug (NSAID) class of medicine.

How should Rekod be stored and disposed of?

How to Store and Dispose of Rekod?

Rekod tablets must be stored at controlled room temperature, typically maintained between 20 C and 25 C (68 F and 77 F). The official label requires the product to be kept in its original container with the cap tightly closed to protect the fast-dissolving tablet from moisture and humidity. Storage areas must be free from excessive heat, and the product must be kept from freezing.

All medicine must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired Rekod must be disposed of according to local regulations or official government guidelines for household waste. The product should not be disposed of by pouring it down a sink or flushing it down a toilet unless explicitly instructed by a regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rekod found in:

A-Z Index: